Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (XTNT): 13 pipeline candidates · ~39 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
38.7 months
D/E 0.60 · 0% dilution
Lead: Approved
13 candidates
N/A
N/A
A transparent, data-derived signal for Xtant Medical Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$61.3M
Cash
$12.2M
Quarterly Burn
$2.1M
Runway
38.7 mo
Revenue
$20.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| cofix | Approved |
| coflex | Approved |
| collagenx | — |
| fibrex | Preclinical |
| hemoblast bellows | — |
| hemoblast bellows | — |
| nanoss strata | Approved |
| osteofactor pro | Preclinical |
| osteovive | — |
| simpligraft | Approved |
Showing 10 of 13 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$4.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,029,206 | $2.2M |
| renaissance technologies llc | 987,410 | $551K |
| geode capital management, llc | 529,214 | $295K |
| crescent grove advisors, llc | 412,024 | $230K |
| nano cap new millennium growth fund l p | 350,000 | $195K |
| vanguard fiduciary trust co | 257,988 | $144K |
| bridgeway capital management, llc | 164,100 | $92K |
| citadel advisors llc | 161,011 | $90K |
| millennium management llc | 132,354 | $74K |
| blackrock, inc. | 115,782 | $65K |
Showing top 10 of 31 institutional holders of Xtant Medical Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Xtant Medical Holdings, Inc.'s pipeline?
Xtant Medical Holdings, Inc. (XTNT) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Xtant Medical Holdings, Inc.'s lead drug candidate?
Xtant Medical Holdings, Inc.'s most advanced tracked candidate is cofix (Approved) for moderate to severe lumbar spinal stenosis.
What is Xtant Medical Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Xtant Medical Holdings, Inc. has approximately 38.7 months of cash runway.
What is Xtant Medical Holdings, Inc.'s market capitalization?
Xtant Medical Holdings, Inc.'s market capitalization is approximately $61.3M.
Who is the CEO of Xtant Medical Holdings, Inc.?
Mr. Sean E. Browne is the chief executive officer of Xtant Medical Holdings, Inc. (XTNT).
Get the full picture on Xtant Medical Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.